As a global health care company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. Our Lovo and Cue Cell Processing Systems are designed for their efficiency and scalability with the goal to deliver these cell and gene therapies to patients as quickly and consistently as possible.

Accellix was founded based on creating a rapid, easy-to-use, automated cell phenotyping platform tailored for point of need environments, focusing on cell therapy and blood characterization. This platform brings next-generation analytical capabilities to cell therapy development and manufacturing QC, enabling the measurement of critical quality attributes at every QC phenotyping interrogation point throughout the manufacturing process and the release of cell therapy products – when and where required. The application of this platform also includes the characterization of blood-derived apheresis products used as source material for oncology, autoimmune, and inflammatory disease research, for donor screening, and for the development and manufacture of advanced therapies. Currently, these assays are performed on standard flow cytometers in centralized labs which require skilled technicians, high maintenance, a separate lab space, and a long turnaround time.

ACTRIS was established in April 2020 to meet the increasing clinical demand for cellular therapeutics to treat various life-threatening diseases. Its vision is to be the national and regional centre of excellence for facilitating discovery, process development, and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and approved products for Singapore. Through its specialised infrastructure and skilled workforce, ACTRIS aims to promote and support the entire value chain of the cell therapy ecosystem by enabling translational research and development, manufacturing, clinical service provision, and commercialisation across the healthcare, academic and industrial sectors. In addition, ACTRIS will also provide value-added services such as workforce training, regulatory facilitation, and the standardisation of ancillary materials pertaining to the delivery of cellular therapy to patients. ACTRIS is a programme of CRIS.

Aenitis specializes in innovative, cost-effective acoustic-based bioprocessing systems designed for advanced cell manipulation. Acoustic technologies enable precise cell sorting, washing, confinement, and rare cell isolation across multiple sectors including Cell and Gene Therapy, Biopharma, Biotechs, CDMOs, and Research laboratories. High flow acoustic cell handling appears as an alternative to the limits of legacy bioprocessing technologies. Aenitis’ acoustic cell handling approach offers significant advantages through high-flow, gentle processing that minimizes mechanical stress while maintaining sterile conditions. This technological solution meets critical GMP compliance requirements and provides a sophisticated alternative to traditional bioprocessing methodologies, delivering superior performance and operational efficiency. Aenitis integrates into the Modular Type Package model with custom design and tuning capabilities based on scalable production machining.

Akron Bio enables the advancement of cell and gene therapies through its portfolio of cytokines and media supplements, as well as its comprehensive suite of manufacturing services, including the production of recombinant proteins and specialized reagents. Akron partners with advanced therapy developers, providing them critical materials and services at the scale, level of compliance, and with the regulatory support necessary to drive novel treatments from discovery to commercialization, thereby addressing critical unmet needs in the patient community.

Anemocyte is an Italian Biotech Manufacturing Organization with a strong focus on the research, development, manufacturing, and analytical services and products to address needs in the field of: pDNA – Plasmids (R&D, Hiqh-Quality, and GMP) for Viral Vector and mRNA;· mRNA – mRNA (R&D) for vaccines and therapeutic treatments. Our experience:> 25 years of research, development and manufacturing experience (from R&D to GMP) in the field of Cell and Gene Therapies and Nucleic Acids.

Aseptic Technologies, part of the SKAN Group, is a global leader in aseptic processing and clean manufacturing solutions for the pharma and biotech industries. We specialize in advanced fill & finish systems, isolator technologies, and custom single-use assemblies, supported by in-house clean injection molding in ISO-certified environments. From early development to commercial production, we deliver integrated, ready-to-use solutions that ensure sterility, compliance, and process efficiency across a wide range of drug products and ATMPs.

Astraveus aspires to radically reduce complexity and cost of cell therapy process development, clinical and commercial manufacturing, thereby making cell-therapies more accessible to patients. Astraveus develops the Lakhesys Benchtop Cell Factory, an automated microfluidic platform for end-to-end cell therapy manufacturing. Due to the radical miniaturization of the Lakhesys Benchtop Cell Therapy Factory, the manufacturing footprint, labor and use of expensive process materials required for cell therapy manufacturing can be reduced by an order of magnitude. The Lakhesys Benchtop Cell Therapy Factory has been developed and tested to enable parallelized and automated cell therapy processing in an end-to-end fashion, i.e. from cellular starting material to the final drug product, thus covering all critical process steps. Through this holistic approach, Astraveus minimizes process development effort and maximizes manufacturing output, thus enabling access to care for patients in need.

AventaCell BioMedical Corp. (“AventaCell”) is among the world leaders devoted to developing novel human-derived products for use in cell culture and tissue regeneration. Helios Bioscience is AventaCell’s product family brand for their products to be used in cell culture and tissue regeneration. AventaCell technologies used in the Helios Bioscience line offer new human-derived solutions for use in translational research of cell and tissue-based therapies to meet the need for animal serum-free cell expansion and production. The demand for safe, efficient and cost-effective cell expansion and production is rapidly increasing with the growth in cell therapy and regenerative medicine research and clinical development. Helios Bioscience products are designed to support expansion and production of a broad range of cells including mesenchymal stem cells and multiple immunocell lines. AventaCell is committed to providing animal serum-free products to accelerate the research, development and commercialization of safe and efficacious cell and tissue-based therapeutics.

Broken String Biosciences is advancing more precise, safe, and effective cell and gene therapies through its cutting-edge technology platforms. The company’s core platform, INDUCE-seq®, was developed as the new gold standard for precise mapping of DNA breaks to measure and quantify on- and off-target genetic edits, crucial for ensuring the efficacy and safety of advanced therapies from discovery through commercialization.

Doing good science is important. So is just doing good. Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and led by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor for over 20 years. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. Helping researchers find new solutions is our main mission every day—but it’s not our only mission. We’re also dedicated to helping identify solutions to other problems facing our world. We believe that all businesses must be responsible and work in partnership with local communities, while seeking to minimize their environmental impact. That’s why we joined 1% for the Planet as its first life science member, and have committed to achieving net-zero emissions by 2029. At CST, we believe in the power and promise of science to solve the challenges we face as a global community. We’re a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our Customers, our communities, and our planet.

Cellex is an end-to-end CDMO based in Cologne, Germany with 10+ years’ experience in manufacturing autologous & allogenic cell and gene therapy (CGT) products. We support customers from preclinical development stages through clinical manufacturing to commercialization. Currently, Cellex is manufacturing several final drug products (FDPs) and cellular intermediates (ITMs) including commercial products. In addition, Cellex offers customized starting materials from healthy donors and patients affected by specific conditions for research, clinical and commercial purposes as well as GDP-compliant logistics services for cellular materials.

At Cellistic, we provide scalable manufacturing solutions for iPSC-based allogeneic cell therapies. Leveraging our Pulse™ + Echo™ Platforms, STAR-CRISPR™ gene editing technology, Allo Chassis™ edited iPS cell lines, and end-to-end CDMO services, we help your programs progress seamlessly from concept to clinical-ready product. With EMA-certified, FDA-compliant GMP manufacturing facilities in Europe, we ensure consistency, scalability, and commercial viability, supported by a team with deep experience in bringing advanced therapies to market.

Cellular Origins is enabling the manufacture of cell therapies at scale. With a flexible, scalable, factory-led approach, Cellular Origins has overcome the unique challenges of cell therapy manufacturing, unlocking access to the same advanced automation that has driven scale in logistics, automotive, and silicon fabrication industries. Cellular Origins' platform, Constellation®, combines mobile robotics and AI with proven bioprocess instruments, providing end-to-end manufacturing, eliminating therapy redevelopment, and speeding up clinical-to-commercial timelines. Cellular Origins is trusted by market leaders such as J&J, Cytiva, Fresenius Kabi, Thermo Fisher Scientific, and Wilson Wolf. Constellation orchestrates seamless automation of existing workflows, reliably scaling manufacture to enable the production of 100,000s of doses of transformative therapies.

Clean Cells, a GMP-certified, FDA-inspected CRO/CMO, provides biosafety and quality control solutions for cell & gene therapy and all biologics. From preclinical to commercial stages, we offer tailored GMP biosafety testing, GMP cell and viral bank production, and secure storage. For 25+ years, our rapid microbiology, viral safety, identity, and purity testing have helped biopharma innovators accelerate advanced therapies. Visit our booth to see how we can support your projects with confidence.

From Discovery to Delivery, Compass Biomedical is innovating what's next in cell culture, tissue repair, and ophthalmic care. Compass's product set, specifically Human Platelet Lysate PLUS(TM), is a pooled human platelet-derived lysate designed for the rapid expansion of human cells in research and clinical applications. PLUS™ is made from transfusion-grade platelets derived from FDA-registered and AABB-accredited blood centers and is a consistent, xeno-free alternative to fetal bovine serum. It is also used as a superior medium compared to human serum for cell culture. It is rich in growth factors and free of animal components and supports the robust proliferation of a wide range of cell types, including MSCs, dendritic cells, fibroblasts, T cells and others. PLUS(TM) is fibrinogen depleted and includes a vast biochemical analysis that is available for both the GMP and Gamma Irradiated Products. It is one of the products that does NOT require use of heparin for cell culturing, making it completely xeno-free for your cell culturing needs and recommendations of the FDA for clinical studies.

Cryotherm, based in Kirchen – Germany, specializes in the construction and manufacture of vacuum super-insulated vessels and transfer lines for cryogenic liquid gases such as helium, nitrogen, oxygen, argon and hydrogen. Our companies’ products and solutions are used in a wide range of applications, including preservation and storage of biological samples, the development of cryobanks, equipment for cryopreservation, as well as storage and transport of liquid helium and nitrogen. Additional areas of application include the transfer of liquefied gases such as LHe, LIN, LAR, LOX and LH2, truck transport tanks with capacity of up to 3,000 liters, cryogenic systems for transport cooling, and advanced control and monitoring technology for cryogenic processes. Cryotherm also offers complete solutions from project planning and manufacturing to installation, delivering innovative and market-oriented concepts tailored to customers’ individual process requirements. Customized solutions include multi-channel pipes for liquid helium, cooling baths for shrinking and chilling processes in the automotive industry, closed-loop systems, valve boxes for LHe and LIN, LHe storage vessels with capacities of up to 20,000 liters, and transport vessels for small tank trucks. In addition, Cryotherm provides a comprehensive after-sales-service, including a 24/7 hotline, service contracts, IQ/OQ qualification, training and commissioning support.

At CytoNiche, we specialize in simplifving the complex world of CGT,especially mesenchymal stem/stromal cells (MSCs) to drive the success of therapeutic commercialization. Our solutions empower you to scale up production with cost-effective, high-quality cells, so that you can focus on what you do best—developing transformative therapeutics. By optimizing access and affordability, we accelerate the timeline for bringin groundbreaking products to market.

Daicel is a diversified technology company with unique capabilities that are being applied to a wide variety of applications, including Medical-grade plastics, Life-saving air bags, Engineered plastics, and the products of our Life Science SBU. Daicel's Life Sciences SBU provides products for the increasingly complex needs of the Pharmaceutical and reladed businesses. Included in these capabilities are the following: Daicel's world-leading Chiral Chromatography products and services, which are routinely used in the development and manufacture of pharmaceutical ingredients. The innovative Actranza® Jet Injection device, used to deliver RNA and DNA vaccines intracellularly without the use of needles, LNPs or other carriers. Pharmaceutical Standards for identification and quantification of drug materials.The most recent entry in our Life Sciences portfolio is an Exosome Isolation System which is designed to process up to 5 liters of feed into 20 ml in less than 2 hours. This proprietary system utilizes both chromatography and tangential flow filtration in a fully automated robust process, allowing for easy and efficient isolation of exosomes, with yield and purity rivalling that of any other method.

Dark Horse Consulting Group (DHCG) integrates Dark Horse Consulting, BioTechLogic and Converge Consulting into one platform for life sciences. DHCG supports clients across the full product lifecycle, from company conception to commercial launch, with expertise spanning all areas of cell and gene therapies. Within DHCG we have a track record of over 1000 clients across more than 20 years of operation. We provide comprehensive technical, operational and strategic support across all aspects of product development, including CMC, regulatory, vendor management, nonclinical, clinical, quality systems, facility compliance, supply chain design/management and oversight, IT infrastructure, commercial launch planning, and more.

Digi-Trax has been providing healthcare compliant labeling, specimen tracking, and patient identification solutions for 40 years. Best known for our proprietary Blood Bank software - HemaTrax® and Cellular Therapy software HemaTrax-CT®, our consultative approach focuses on essential workflows for Blood Banks, Cell Therapy, Plasma Centers, Laboratory Services, and Acute Care Hospital Patient Care areas. We have also developed an industry-compliant suite of Downtime and Emergency Solutions in these spaces that has proven to deliver critical / value-added assets to our clients and prospects.

The European Bank for iPSCs (EBiSC, www.EBiSC.org) is a not-for-profit iPSC repository which collects, safeguards and shares iPSC lines to commercial and academic researchers. EBiSC is active in iPSC research through making iPSC lines available and by collaborating with iPSC researchers worldwide in the development of new iPSC tools and assays using expertise in iPSC derived cells, cryopreservation and upscaling. IPSC lines in the EBiSC catalogue have been made and deposited by both EBiSC partners and external research organisations including non-profit and commercial organisations. The collection includes iPSCs derived from individuals with diagnosed diseases and apparently healthy controls, and genetically modified isogenic sub-clones. EBiSC iPSCs are derived from both biologically male and female donors, spanning ages 0-89 years and covering more than 45 different diseases including neurodegenerative, neurological, cardiac, liver, eye, blood, kidney and skeletomuscular disorders. EBiSC continues to welcome new iPSC line cohorts representing novel diseases, genotypes or tools for use by the iPSC research community. Get in touch via Contact@EBiSC.org.

Grifols Bio Supplies business unit is a leader in human biological materials collected from our own network of blood and plasma centers to be used by pharmaceutical and biotechnology companies for drug manufacturing, the life-science industry for research, and in vitro diagnostic companies for the production of reagents and controls. Grifols is a global healthcare company committed to improving people’s health and well-being. Our more than 24,000 employees in more than 30 countries and regions develop, produce, and market plasma-derived medicines as well as innovative biotech and diagnostic solutions in more than 110 countries.

Fraunhofer IPT and Harro Höfliger bridge the gap between laboratory development and commercial production of ATMP therapeutics. The production of ATMPs (Advanced Therapy Medicinal Products) of the highest quality requires individual production facilities and specific services. The focus here is on careful handling of the cell material. The Fraunhofer Institute for Production Technology IPT and Harro Höfliger combine science and marketable technology to develop efficient solutions – fully automated and optimally designed for the product.

"LumaCyte is at the forefront of bioanalytics, pioneering innovative solutions that enhance our understanding of cellular behavior. Dedicated to advancing the field of cellular PAT analytics, LumaCyte leverages cutting-edge technology to offer unparalleled insights into the biophysical and biochemical properties and behaviors of single cells. LumaCyte’s groundbreaking bioanalytics platform, Radiance®, offers a cutting-edge, real-time, label-free approach to single-cell analysis. By leveraging Laser Force Cytology™ (LFC), Radiance® precisely quantifies innate cellular responses, entirely eliminating the need for antibody or genetic labeling. This revolutionary technology measures nuanced phenotypic changes based solely on cells' intrinsic biophysical and biochemical properties as they react to their environment or treatment. Discover more about our innovative technology at LumaCyte.com."

"Founded in 1984, MAK‑SYSTEM is a global leader in healthcare software solutions, specializing in the secure and efficient management of blood, plasma, tissue, and cellular products. Headquartered in the UK with operations spanning over 35 countries, our mission is to empower clinicians, donors, and patients through technology-driven innovation.

 
Our integrated software portfolio supports end‑to‑end workflows — from donation and processing to transfusion, cell and gene therapy, and tissue banking. We combine robust automation, traceability, and compliance capabilities to meet regulatory standards such as FDA, AABB, FACT, ISBT 128, and European guidelines. With more than 30 million donation events annually managed through our systems, MAK‑SYSTEM’s platforms are trusted by leading hospitals, blood centers, plasma facilities, and biotech organizations worldwide.

 
In 2022, we launched MAK.care, a managed services platform that delivers our software as a cloud-based, secure, and scalable solution — allowing clients to focus on patient care while we maintain the digital ecosystem. Driven by a culture of innovation, integrity, and partnership, MAK‑SYSTEM is committed to pushing the boundaries of digital healthcare—ensuring safety, compliance, and improved outcomes in transfusion, cell therapy, and beyond."

Mill Creek Life Sciences was the first company to commercially sell human platelet lysate (hPL). Born in a cGMP cell therapy lab, our human platelet lysates have been used to grow cells for thousands of patients globally in more than 50 Phase I, II, and III clinical trials for more than a decade. Our hPL products are derived from human platelets and offer unparalleled cell growth in cellular therapy.

Mill Creek Life Sciences is committed to discovering and applying innovative approaches to cellular therapy and patient care. Our leading products are PLTGold® and PLTMax®, with gamma irradiated versions available. Initially developed for use with MSCs, our human platelet lysates have evolved into a platform technology that has been used with successful results with many other cell types and applications, including 2D and suspension cultures, as well as organoids. Additional cell types grown with our products include T cells, NK cells, tumor cells, endothelial cells, iPSCs, and more.

Mill Creek Life Sciences was founded with a singular purpose in mind: to bring new solutions to accelerate cellular therapies for patients. For us it is about quality, innovation and customer service. We work closely with our customers, helping fulfill their needs and supporting them through analyzing and troubleshooting specific applications when needed.

MVE Biological Solutions is the global leading manufacturer of cryogenic storage and shipping devices. For over 60 years, we set the standard for storing biological materials at low temperatures. MVE is the preferred brand for cryogenic equipment in various application areas, including biopharma, cell and gene therapies, storage of cord blood and stem cells, medical research facilities, government institutions, IVF centers, hospitals and clinics, and animal husbandry and livestock.

NecstGen is a non-profit CDMO and centre of excellence for Cell and Gene Therapy, located in a purpose-built GMP facility on the largest bio-cluster in the Netherlands, Leiden Bio Science Park. Here, NecstGen provides critical contract development, manufacturing and rental services to academic and industrial therapy developers to deliver a new generation of therapies to patients.

The German pharmaceutical company Nordmark develops and produces ingredients and drug products through all stages of the value chain and offers extensive support for your project from development to market. As the largest manufacturer of collagenase, Nordmark Biochemicals is focused on Collagenase NB products for tissue dissociation and their worldwide distribution. Due to the wide range of enzymes offered, from natural blend to highly purified, our products are suitable for the isolation of various cell types for research and clinical applications. Our portfolio includes translational enzymes-- research and GMP grade collagenase and neutral protease products – to simplify your path from research to the clinic. Our pharmaceutical manufacturing standard ensures stringent quality control, a high lot-to-lot consistency and the superior quality guarantees cell viability and high yields. Supporting documentation and access to the drug master file registered with the FDA are available for GMP grade users. Our Collagenase NB 6 GMP Grade is a fast and reliable tool for isolation of many cell types. For more information, visit www.nordmark-biochemicals.com or contact us at Collagenase@nordmark-biochemicals.com

Octapharma are the world’s largest privately owned plasma fractionator, with over 40 years of experience in the industry. Octapharma produce a range of GMP grade plasma derived proteins and serum media additives for the Life Sciences sector. Suitable for Cell & Gene Therapy, Vaccine Development, RNA/DNA Therapeutics, In Vitro Diagnostics, Immunoassays, and wider CDMO/CRO/CMO usage. All proteins are GMP grade, produced to a medicinal standard, and double-pathogen reduced. Bespoke and tailored regulatory documents can also be supplied to support approval body submission where material is listed as an excipient. With several concentrations available for each product, we can confidently support small-scale laboratory use, right through to end product manufacture, supporting all paces of company scale-up.

OriGen Biomedical is a leading producer of cryopreservation and cell culture products. OriGen’s focus is to produce a range of products to support the treatment of cancer, genetic conditions, and other life-threatening diseases. OriGen Biomedical® products are designed with the patient and user in mind and we strive to maintain excellent customer service to ensure that patient care is the priority. OriGen is a growing, privately-held medical device manufacturer founded in 1997 and headquartered in Austin, Texas. Quality is the foundation of all product designs at OriGen, and each product is produced with the intention of improving patient health. OriGen is certified annually to ISO 13485 standards and regularly inspected by the FDA, MDSAP, ISO certification organizations, and our customers.

OXB (formerly Oxford Biomedica) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors;the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ polyclonal stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx’s iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available "off-the-shelf" along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit www.pluristyx.com.

Qkine is a leading manufacturer of high-purity, animal origin-free growth factors, cytokines, and complex bioactive proteins for life science applications, including stem cell and organoid culture. Headquartered in Cambridge, UK, Qkine addresses critical biological, quality, and scalability challenges through proprietary recombinant protein production processes combined with advanced protein engineering techniques. Our commitment to innovation supports emerging fields such as 3D stem cell models, organoids, cellular agriculture, cell therapy, regenerative medicine, and organ-on-a-chip technologies. By delivering reliable tools for research and biomanufacturing, Qkine aims to accelerate the impact of these technologies on human health and wellbeing. Please visit qkine.com, email customerservice@qkine.com or follow us on LinkedIn.

Refeyn pioneers analytical instruments that put AAV mass measurement capabilities within easy reach for scientists. Refeyn’s unique products measure the mass of individual AAV capsids, providing vital insights for AAV sample characterization and manufacturing process development. Our instruments feature mass photometry technology, which uses light to weigh single particles in solution. It can measure AAV capsids as well as proteins, nucleic acids and complexes. Providing intuitive data in minutes, mass photometry enables scientists to optimize R&D processes and focus on innovation. Refeyn’s mission is to transform analytical workflows in the life sciences, biopharma and beyond, using the power of light.

REPROCELL’s vision is to advance human health by delivering cutting-edge products, services, and partnerships that drive the future of Regenerative Medicine. We specialize in the manufacture of custom GMP-grade Master Cell Banks (MCB) of iPSCs, iPSC-derived MSCs (iMSCs), and conventional MSCs, developed in compliance with FDA, EMA, and PMDA regulatory standards. Our ready-to-use and custom Clinical iPSC Seed Clones are generated using our proprietary StemRNA™ Clinical footprint-free Reprogramming Technology. Sponsors can first evaluate pilot clones—with full genetic integrity and characterization data—before committing to GMP MCB generation or clinical gene editing, minimizing risk and ensuring the most suitable clone is advanced into development. For drug discovery, REPROCELL offers preclinical CRO services with unique expertise in custom assay development using live human tissues and advanced 3D tissue models. These systems deliver more predictive results and accelerate decision-making in translational research. Through our Central Laboratory Services, we support global clinical trials with consistent, quality-controlled sample handling—from routine PBMC processing to advanced genomic, proteomic, and cellular analyses—ensuring reliability across complex clinical research programs. Over the past decade, REPROCELL has built a comprehensive regenerative medicine workflow through strategic acquisitions, uniting capabilities in human tissue acquisition (BioServe®), RNA reprogramming (Stemgent®), 3D cell culture (Alvetex®), and drug discovery (Biopta®). Today, this expertise extends into the development of clinical-grade stem cells, bridging discovery and therapeutic application. By combining scientific innovation with regulatory compliance, REPROCELL empowers partners with the tools, technologies, and services to advance next-generation regenerative therapies worldwide.

RoosterBio accelerates stem cell and exosome product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality stem cells, bioprocess media, genetic engineering tools, and exosome production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing under GMP at lower cost and higher productivity. RoosterBio is driven by client success to create a world where safe, effective advanced therapies are rapidly developed on a global scale.

Scinus Cell Expansion develops technologies and services that advance cell therapy and regenerative medicine. Our mission is to help make cell therapies accessible to patients worldwide. We are commercializing Osilaris™, a closed, GMP-compliant bioreactor system for stem cell cultivation. Osilaris™ provides a cost-effective, controlled alternative to conventional production, enabling expansion of adherent cells, suspension cells, and organoids within a single closed system. The system’s patented, single-use, volume-expandable culture bags allow large-scale expansion in a homogenized, low-shear environment—ideal for scaling out (stem) cell cultures. In addition, Scinus supports clients in translating cell culture processes into commercial-scale, GMP-compliant production strategies. For more information, please visit our website (www.scinus.com).

SCTbio is a trusted Contract Development and Manufacturing Organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), including autologous cell-based therapies and viral vectors. Headquartered in Prague, Czech Republic, SCTbio operates under cGMP standards and is part of the PPF Biotech network. The company offers end-to-end services across the full lifecycle of cell and gene therapy development—from apheresis collection and process development to clinical and commercial manufacturing, quality control, QA/QP release, and global logistics. With over a decade of experience inherited from the SOTIO Group, SCTbio combines deep scientific expertise with a client-focused approach, delivering tailored solutions for complex therapeutic products such as CAR-T cells, dendritic cell vaccines, and genetically modified constructs. Its facilities are designed to ensure physical segregation of viral and non-viral components, minimizing cross-contamination risks. SCTbio’s mission is to accelerate the journey from bench to bedside by providing superior GMP manufacturing services and fostering innovation in regenerative medicine and oncology. Through a validated network of over 150 apheresis centers across Europe and the USA, SCTbio ensures reliable cell sourcing and streamlined operations for its partners worldwide. Learn more at www.sctbio.com.

STEMSOFT Software offers a fully electronic solution designed to document all phases of patient care and product manufacturing. Our software solutions allow you to save time, comply with quality and accreditation requirements, and easily access a complete dataset for analysis. The latest ICCBBA specified ISBT-128 Cellular Therapy collection label templates are provided via our STEMSOFT LAB product, and our batch record software is configurable and workflow driven, allowing you to focus on producing your products.

Founded in 2019 in Tianjin, China, Tasly Institute of Life Rejuvenation (TILR) aims to transform disease-centered medication into personalized healthcare through AI-enabled, cell-based organ rejuvenation. Company’s Vision Life rejuvenation relies on the structural and functional integrity of the vascular system, particularly microcirculation. Mesenchymal stromal cells (MSCs) maintain capillary endothelial integrity, regulate permeability, and respond to microenvironmental alterations by releasing cytokines that activate tissue rejuvenation. Industrialization of medicinally active MSCs for life rejuvenation constitutes a critical component of personalized healthcare. Key Achievements TILR defined the property, purity, and potency of MSCs derived from different tissues, developed standard procedures for safety and efficacy measurements of MSCs in clinical applications, and supported clinical trials of MSC treatments for severe disease conditions approved by US-FDA and China CDE.

Our Homeworld of Cell Culture Media With over 30 years of biochemical manufacturing expertise, TRINA is a trusted contract manufacturing and supplying partner for leading producers of cell culture media. Our premium-grade components and auxiliary raw materials — including human serum albumin, human transferrin, platelet lysate, recombinant insulin and more — are specifically developed and tailored for media formulation and downstream manufacturing.

VectorBuilder is a rapidly growing biotechnology organisation. Our revolutionary online Vector Design Studio has become popular with researchers around the world for its rich functionalities and highly intuitive user interface. We specialise research products and services such as vector cloning, virus packaging, library construction, stable cell line generation, COVID-19 research reagents, AAV capsid evolution and biodistribution and GMP manufacturing of clinical-grade plasmid DNA and viruses, taking your design right through to therapy.

VitaCyte manufactures, supplies, and sells defined Clostridium histolyticum collagenase & neutral protease enzymes from other microbial species for cell isolation or recovery of cells after culture. VitaCyte offers three categories of purified-defined collagenase products: lower-cost natural PD Collagenases and higher-cost natural and recombinant collagenases. These GMP-grade products are consistently manufactured (i.e., minimal lot-to-lot variability) and are >95% pure. The recombinant collagenase is animal-origin-free. VitaCyte also offers four purified GMP-Grade neutral protease products: AM Protease, BP Protease (Dispase equivalent enzyme), Clostripain, and Thermolysin. Each protease can be used in a broad range of applications. All these enzymes are animal-origin-free except clostripain. VitaCyte’s rigorous characterization of collagenase enzymes led to the development of four distinct, purified, defined collagenase-protease mixtures used to isolate specific cell populations. These purified-defined products replaced the inconsistent traditional collagenase products that required lot testing before purchase. VitaCyte developed a simplified procedure for optimizing collagenase-protease enzyme mixtures used in enzyme-mediated cell isolation procedures. The rational design method for optimizing tissue dissociation enzymes uses two products containing purified collagenase, one of which also contains neutral protease. The benefits of this approach are that the client knows the biochemical properties of the enzymes used in their manufacturing process, can share these results with regulatory authorities, and has access to a second source of enzymes.